WallStSmart

Intuitive Surgical Inc (ISRG)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Intuitive Surgical Inc generates 122282% more annual revenue ($10.58B vs $8.65M). NNNN leads profitability with a 74.1% profit margin vs 28.1%. ISRG trades at a lower P/E of 48.8x. ISRG earns a higher WallStSmart Score of 64/100 (C+).

ISRG

Buy

64

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 6.0Quality: 7.8
Piotroski: 4/9Altman Z: 5.89

NNNN

Buy

52

out of 100

Grade: C-

Growth: 5.3Profit: 9.5Value: 4.0Quality: 6.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ISRGUndervalued (+77.9%)

Margin of Safety

+77.9%

Fair Value

$1896.32

Current Price

$422.06

$1474.26 discount

UndervaluedFair: $1896.32Overvalued

Intrinsic value data unavailable for NNNN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ISRG5 strengths · Avg: 9.2/10
Operating MarginProfitability
30.9%10/10

Strong operational efficiency at 30.9%

Altman Z-ScoreHealth
5.8910/10

Safe zone — low bankruptcy risk

Market CapQuality
$142.48B9/10

Large-cap with strong market position

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

Revenue GrowthGrowth
23.0%8/10

Revenue surging 23.0% year-over-year

NNNN4 strengths · Avg: 10.0/10
Return on EquityProfitability
32.3%10/10

Every $100 of equity generates 32 in profit

Profit MarginProfitability
74.1%10/10

Keeps 74 of every $100 in revenue as profit

Operating MarginProfitability
59.1%10/10

Strong operational efficiency at 59.1%

Revenue GrowthGrowth
73.9%10/10

Revenue surging 73.9% year-over-year

Areas to Watch

ISRG3 concerns · Avg: 3.3/10
PEG RatioValuation
2.164/10

Expensive relative to growth rate

Price/BookValuation
8.6x4/10

Trading at 8.6x book value

P/E RatioValuation
48.8x2/10

Premium valuation, high expectations priced in

NNNN4 concerns · Avg: 2.8/10
EPS GrowthGrowth
2.8%4/10

2.8% earnings growth

Market CapQuality
$684.26M3/10

Smaller company, higher risk/reward

P/E RatioValuation
103.9x2/10

Premium valuation, high expectations priced in

Price/BookValuation
33.3x2/10

Trading at 33.3x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ISRG

The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 28.1% and operating margin at 30.9%. Revenue growth of 23.0% demonstrates continued momentum.

Bull Case : NNNN

The strongest argument for NNNN centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 74.1% and operating margin at 59.1%. Revenue growth of 73.9% demonstrates continued momentum.

Bear Case : ISRG

The primary concerns for ISRG are PEG Ratio, Price/Book, P/E Ratio. A P/E of 48.8x leaves little room for execution misses.

Bear Case : NNNN

The primary concerns for NNNN are EPS Growth, Market Cap, P/E Ratio. A P/E of 103.9x leaves little room for execution misses.

Key Dynamics to Monitor

NNNN is growing revenue faster at 73.9% — sustainability is the question.

ISRG generates stronger free cash flow (809M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ISRG scores higher overall (64/100 vs 52/100), backed by strong 28.1% margins and 23.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intuitive Surgical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.

Anbio Biotechnology Class A Ordinary Shares

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.

Want to dig deeper into these stocks?